Clinical Trials at Penn Medicine: Mesothelioma May Benefit From Immuno-Gene Therapy


May 6, 2010

Cancer Survivor Surviving Mesothelioma

Gene therapy is a promising treatment for mesothelioma, but it has been slow to make its way into clinical use because delivering enough therapeutic genes to effectively kill large numbers of cancer cells has proved challenging. Recently, mesothelioma researchers have been focusing on a method called immuno-gene therapy, which transfers just enough genetic material to trigger the patient’s own immune system to fight the cancer, according to a recent review published in the American Journal of Respiratory Cell and Molecular Biology... Read More

The University of Pennsylvania is developing a number of experimental clinical trial programs for malignant pleural mesothelioma, including gene therapy. The next clinical trial will evaluate two different chemotherapy regimens in combination with intrapleural adenoviral-mediated interferon-alpha gene transfer.

For more information regarding this and other clinical trials at the University of Pennsylvania, contact Adri Recio, RN at 215-573-6760 or email: arecio@mail.med.upenn.edu